Advicenne Logo

Advicenne

Develops and commercializes therapies for rare renal diseases for patients of all ages.

ALDVI | PA

Overview

Corporate Details

ISIN(s):
FR0013296746 (+1 more)
LEI:
969500YT5VMEYAYODW34
Country:
France
Address:
262 RUE DU FAUBOURG SAINT-HONORE, 75008 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Advicenne is a specialty pharmaceutical company dedicated to developing, commercializing, and marketing innovative treatments for rare diseases. The company's primary focus is on improving the lives of patients with rare renal (nephrological) conditions. Leveraging more than a decade of research and development, Advicenne specializes in creating therapies suitable for both children and adults, underscoring its commitment to making groundbreaking treatments accessible to patients of all ages in international markets.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 11:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 175.1 KB
2025-11-04 11:30
Regulatory News Service
Inside Information / Other news releases
English 143.4 KB
2025-07-28 07:30
Regulatory News Service
Inside Information / Other news releases
English 164.8 KB
2025-07-28 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 178.7 KB
2025-07-25 07:30
Earnings Release
Inside Information / Other news releases
English 177.4 KB
2025-07-25 07:30
Earnings Release
Informations privilégiées / Autres communiqués
French 190.6 KB
2025-05-16 08:00
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 114.8 KB
2025-04-29 18:00
Registration Form
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
French 182.1 KB
2025-04-29 18:00
Registration Form
Annual financial and audit reports / Terms of availability of the annual financ…
English 152.3 KB
2025-03-27 19:12
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 324.3 KB
2025-03-27 19:12
Earnings Release
Inside Information / News release on accounts, results
English 336.8 KB
2025-01-23 18:30
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
French 233.9 KB
2025-01-23 18:30
Earnings Release
Inside Information / Information on annual revenues
English 243.6 KB
2024-12-19 18:00
M&A Activity
Inside Information / Other news releases
English 196.5 KB
2024-12-19 18:00
M&A Activity
Informations privilégiées / Autres communiqués
French 163.2 KB

Automate Your Workflow. Get a real-time feed of all Advicenne filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Advicenne

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Advicenne via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-10-04 N/A Other Other 1,452,282 3,499,999.62 EUR
2023-10-04 N/A Other Buy 41,493 99,998.13 EUR
2023-10-02 N/A Other Other 414,937 999,998.17 EUR
2023-09-21 N/A Other Sell 22,336 22.34 EUR
2023-09-15 N/A Other Sell 134,492 13.45 EUR

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.